Royal Society?

The Royal Society, chartered in 1660, is the senior scientific academy of the United Kingdom and holds the primary authority over the admission and publication of fellows in natural philosophy and experimental science. By the early twentieth century it had become the institutional centre of British scientific life, hosting weekly meetings of its Fellowship in London and maintaining laboratories across Britain and the Commonwealth.

The trajectory of the Society changed fundamentally after 1928, when the absence of any chemical antimicrobial breakthrough after the early sulfonamide discoveries became clear. Where the Society's medical fellows had once expected the nineteenth-century advances in diphtheria antitoxin and basic bacteriology to be followed by a parade of chemical cures, the 1930s and 1940s brought no such breakthroughs. Surgery remained perilous; childbed fever and wound septicaemia continued to kill at pre-antibiotic rates; casualties in the 1943 Sicily campaign revealed that systemic bacterial infection could not be chemically controlled.

By 1950, the Society had begun to redirect the work of its medical and biological fellows toward what became the permanent foundation of British medicine: the study of bacterial genetics, the refinement of serum therapy, and the architectural and administrative principles that would become known as asepsis maximalism. A generation of Society fellows who had trained expecting to witness the chemical conquest of bacterial disease instead became architects of prevention.

The Society's response took concrete institutional form after the Bacillary Congress of Geneva in 1952. The Congress, which standardized infection-control doctrine across nations, drew substantially on the research programs and theoretical positions already established within the Society's own committees. The Society appointed a permanent Committee on Infection Science in 1953, charged with coordinating British research into serum therapy efficacy, bacteriological education, and the statistical methods by which infection outcomes could be measured and compared across hospitals.

A decisive shift came with the appointment of Dorothy Umezaki to a Foreign Member fellowship in 1978, the same year her serum therapy trials began to demonstrate clinical efficacy equivalent to the azo drugs for several major pathogenic bacteria. Umezaki's election recognized that the theoretical and practical foundations of the Halloway-Umezaki method had been built in part on decades of prior Society-sponsored research into bacterial toxicology and serum preparation. The Society's fellows had not produced the breakthrough themselves, but they had maintained the intellectual infrastructure—the journals, the collaborative networks with continental institutes, the standardized measurement protocols—that made the breakthrough possible when it came.

The Society's publishing role became consequential in ways that reflected this shift. The Philosophical Transactions of the Royal Society, the Society's flagship journal founded in 1665, had by the 1960s become the primary British venue for papers on serum pharmacology, hospital design, and the epidemiological measurement of infection. Papers on traditional chemistry and physics continued to appear, but the volume and prominence of infection-related research grew steadily through the 1970s and 1980s. Archives of the Society show that by 1985, roughly one-third of all papers accepted for publication concerned some aspect of bacterial disease or its prevention.

The Society's relationship with Bayer AG and its archives became a matter of institutional concern after the opening of the Bayer finding guide in 1994. Fellows recognized that the azo drugs, produced almost entirely by Bayer from the 1930s onward, represented the only successful chemical intervention in systemic bacterial infection. The Society's Committee on Scientific History commissioned a comprehensive study of Bayer's sulfonamide manufacture and distribution during World War II, leading to the acquisition of microfilm copies of key production records and the organization of a specialized archive devoted to the chemical history of the azo drugs.

By the early twenty-first century, the Society maintained active research programs in serum therapy clinical trials, hospital epidemiology, and the microbiology of antibiotic resistance—a phenomenon that, in the absence of chemical antimicrobials, manifested differently than in worlds where multiple drug classes competed. The Society's fellows trained in a medical culture where bacterial infection remained an existential threat to human life, and where the prevention of contamination and the passive immunization of vulnerable populations remained the only reliable defenses. Its laboratories, its fellowship structure, and its publication programs had all been reorganized around this reality, not as a temporary expedient but as the permanent framework of modern medicine.